George Yancopoulos - Feb 15, 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Bd. Co-Chair, President & CSO, Director
Signature
/s/**George D. Yancopoulos
Stock symbol
REGN
Transactions as of
Feb 15, 2024
Transactions value $
-$48,863,868
Form type
4
Date filed
2/20/2024, 04:03 PM
Previous filing
Jan 4, 2024
Next filing
May 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $69M +173K +22.95% $399.66 925K Feb 15, 2024 Direct
transaction REGN Common Stock Tax liability -$118M -124K -13.36% $953.83 802K Feb 15, 2024 Direct
holding REGN Common Stock 5.89K Feb 15, 2024 By 401(k) Plan
holding REGN Common Stock 180K Feb 15, 2024 By Trust for Chldn. F1
holding REGN Common Stock 121K Feb 15, 2024 by 2022 GRAT I
holding REGN Common Stock 158K Feb 15, 2024 by 2022 GRAT II

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -173K -100% $0.00* 0 Feb 15, 2024 Common Stock 173K $399.66 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As investment trustee of trusts for the benefit of the reporting person's children.
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.